Study of alveolar rhabdomyosarcoma copy number alterations by single nucleotide polymorphism analysis

Applied Immunohistochemistry and Molecular Morphology

Volumn 22, Issue 3, 2014, Pages 213-221

  Lynn, Miriam ^a   Shah, Naisha ^a   Conroy, Judith ^a   Ennis, Sean ^a   Morris, Thomas ^a   Betts, David ^a   O'Sullivan, Maureen ^a,b  

^a National Children's Research Centre   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

Author keywords

Alveolar rhabdomyosarcoma; BCR; Copy number alteration; Dicer1; GPC5; IGF1R; MycN; Snp

Indexed keywords

CENPF PROTEIN; CYCLIN DEPENDENT KINASE 4; DDX1 PROTEIN; DTL PROTEIN; GLYPICAN; GLYPICAN 5; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HIGH MOBILITY GROUP A2 PROTEIN; MYC PROTEIN; MYCN PROTEIN; PROTEIN MDM2; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX7; UNCLASSIFIED DRUG; BCR PROTEIN, HUMAN; BREAKPOINT CLUSTER REGION PROTEIN; DEAD BOX PROTEIN; DICER1 PROTEIN, HUMAN; GLI PROTEIN; GPC5 PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN RECEPTOR; LRP1B PROTEIN, HUMAN; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PAIRED BOX TRANSCRIPTION FACTOR; PAX3 FOXO1A FUSION PROTEIN, HUMAN; PAX3-FOXO1A FUSION PROTEIN, HUMAN; PAX7 PROTEIN, HUMAN; RIBONUCLEASE III; SOMATOMEDIN C RECEPTOR; TRANSACTIVATOR PROTEIN; WNT PROTEIN; WNT6 PROTEIN, HUMAN;

ADOLESCENT; AMPLICON; ARTICLE; CHILD; CHROMOSOME 11; CHROMOSOME 12; CHROMOSOME 14; CHROMOSOME 15; CHROMOSOME 17; CHROMOSOME 2; CHROMOSOME 20; CHROMOSOME 6; CHROMOSOME 7; CHROMOSOME 8; CHROMOSOME 9; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA EXTRACTION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENOTYPE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; GENE AMPLIFICATION; GENETICS; INFANT; LUNG TUMOR; MORTALITY; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; SURVIVAL;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 14; COHORT STUDIES; DEAD-BOX RNA HELICASES; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; FEMALE; GENE AMPLIFICATION; GLYPICANS; HUMANS; INFANT; LUNG NEOPLASMS; MALE; NUCLEAR PROTEINS; ONCOGENE PROTEINS; ONCOGENE PROTEINS, FUSION; PAIRED BOX TRANSCRIPTION FACTORS; PAX7 TRANSCRIPTION FACTOR; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-BCR; RECEPTOR, IGF TYPE 1; RECEPTORS, LDL; RHABDOMYOSARCOMA; RIBONUCLEASE III; SURVIVAL ANALYSIS; TRANS-ACTIVATORS; TRANSCRIPTION FACTOR CHOP; WNT PROTEINS;

EID: 84910108437     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PDM.0000000000000030     Document Type: Article

References (42)

1. Parham DM, Ellison DA. Rhabdomyosarcomas in adults and children: An update. Arch Pathol Lab Med. 2006;130:1454-1465.
2. Hollowood K, Fletcher CD. Rhabdomyosarcoma in adults. Semin Diagn Pathol. 1994;11:47-57.
3. Galili N, Davis RJ, Fredericks WJ, et al. Fusion of a fork head domain gene to PAX3 in the solid tumor alveolar rhabdomyosarcoma. Nat Genet. 1993;5:230-235.
4. Shapiro DN, Sublett JE, Li B, et al. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res. 1993;53:5108-5112.
5. Davis RJ, D'Cruz CM, Lovell MA, et al. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res. 1994;54:2869-2872.
6. Scheidler S, Fredericks WJ, Rauscher FJ III, et al. The hybrid PAX3- FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture. Proc Natl Acad Sci USA. 1996;93:9805-9809.
7. Anderson JR, Barr FG, Hawkins DS, et al. Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature. J Clin Oncol. 2010;28:e587-e588.
8. Williamson D, Missiaglia E, de Reyniès, A, et al. Fusion genenegative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol. 2010;28:2151-2158.
9. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: A report from the children's oncology group. J Clin Oncol. 2002;20:2672-2679.
10. Duan F, Smith LM, Gustafson DM, et al. Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: A report from the Children's Oncology Group. Genes Chromosomes Cancer. 2012;51:662-674.
11. Wang K, Li M, Hadley D, et al. Penn CNV: An integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res. 2007;17:1665-1674.
12. Forus A, Florenes VA, Maelandsmo GM, et al. Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: Some amplica do not include MDM2. Cell Growth Differ. 1993;4:1065-1070.
13. Forus A, Weghuis DO, Smeets D, et al. Comparative genomic hybridization analysis of human sarcomas: II. Identification of novel amplicons at 6p and 17p in osteosarcomas. Genes Chromosomes Cancer. 1995;14:15-21.
14. Driman D, Thorner PS, Greenberg ML, et al. MYCN gene amplification in rhabdomyosarcoma. Cancer. 1994;73:2231-2237.
15. Bayani J, Thorner P, Zielenska M, et al. Application of a simplified comparative genomic hybridization technique to screen for gene amplification in pediatric solid tumors. Pediatr Pathol Lab Med. 1995;15:831-844.
16. Hachitanda Y, Toyoshima S, Akazawa K, et al. N-myc gene amplification in rhabdomyosarcoma detected by fluorescence in situ hybridization: its correlation with histologic features. Mod Pathol. 1998;11:1222-1227.
17. Williamson D, Lu YJ, Gordon T, et al. Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J Clin Oncol. 2005;23:880-888.
18. Tonelli R, McIntyre A, Camerin C, et al. Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy. Clin Cancer Res. 2012;18:796-807.
19. Barr FG, Duan F, Smith LM, et al. Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: A report from the Children's Oncology Group. Genes Chromosomes Cancer. 2009;48:661-672.
20. Missiaglia E, Selfe J, Hamdi M, et al. Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: An approach to identify candidate genes involved in tumor development. Genes Chromosomes Cancer. 2009;48:455-467.
21. Goldstein M, Meller I, Issakov J, et al. Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: A cytogenetic and molecular analysis of primary tumors. Neoplasia. 2006;8:332-343.
22. Gordon AT, Brinkschmidt C, Anderson J, et al. A novel and consistent amplicon at 13q31 associated with alveolar rhabdomyosarcoma. Genes Chromosomes Cancer. 2000;28:220-226.
23. Williamson D, Selfe J, Gordon T, et al. Role for amplification and expression of glypican-5 in rhabdomyosarcoma. Cancer Res. 2007;67:57-65.
24. Bridge JA, Liu J, Qualman SJ, et al. Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes. Genes Chromosomes Cancer. 2002;33:310-321.
25. Kikuchi K, Rubin BP, Keller C. Developmental origins of fusionnegative rhabdomyosarcomas. Curr Top Dev Biol. 2011;96:33-56.
26. Singh S, Vinson C, Gurley CM, et al. Impaired Wnt signaling in embryonal rhabdomyosarcoma cells from p53/c-fos double mutant mice. Am J Pathol. 2010;177:2055-2066.
27. Paulson V, Chandler G, Rakheja D, et al. High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromosomes Cancer. 2011;50:397-408.
28. Belyea B, Kephart JG, Blum J, et al. Embryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targeting. Sarcoma. 2012;2012:406239.
29. Shukla N, Ameur N, Yilmaz I, et al. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res. 2012;18:748-757.
30. Pressey JG, Anderson JR, Crossman DK, et al. Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2011;57:930-938.
31. Roma J, Almazán-Moga A, Sánchez de Toledo J, et al. Notch, wnt, and hedgehog pathways in rhabdomyosarcoma: from single pathways to an integrated network. Sarcoma. 2012;2012:695603.
32. Pandita A, Zielenska M, Thorner P, et al. Application of comparative genomic hybridization, spectral karyotyping, and microarray analysis in the identification of subtype-specific patterns of genomic changes in rhabdomyosarcoma. Neoplasia. 1999;1:262-275.
33. Bennicelli JL, Fredericks WJ, Wilson RB, et al. Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. Oncogene. 1995;11:119-130.
34. Patel JH, Loboda AP, Showe MK, et al. Analysis of genomic targets reveals complex functions of MYC. Nat Rev Cancer. 2004;4:562-568.
35. Bouron-Dal Soglio D, Rougemont AL, Absi R, et al. SNP genotyping of a sclerosing rhabdomyosarcoma: reveals highly aneuploid profile and a specific MDM2/HMGA2 amplification. Hum Pathol. 2009;40:1347-1352.
36. Zibat A, Missiaglia E, Rosenberger A, et al. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma. Oncogene. 2010;29:6323-6330.
37. Hoppener JW, de Pagter-Holthuizen P, Geurts van Kessel AH, et al. The human gene encoding insulin-like growth factor I is located on chromosome 12. Hum Genet. 1985;69:157-160.
38. Chuang TH, Xu X, Kaartinen V, et al. Abr and Bcr are multifunctional regulators of the Rho GTP-binding protein family. Proc Natl Acad Sci USA. 1995;92:10282-10286.
39. Kinoshita Y, Tamiya S, Oda Y, et al. Establishment and characterization of malignant rhabdoid tumor of the kidney. Oncol Rep. 2001;8:43-48.
40. Tomari Y, Zamore PD. Perspective: machines for RNAi. Genes Dev. 2005;19:517-529.
41. Kumar MS, Pester RE, Chen CY, et al. Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev. 2009;23:2700-2704.
42. Cross SF, Arbuckle S, Priest JR, et al. Familial pleuropulmonary blastoma in Australia. Pediatr Blood Cancer. 2010;55:1417-1419.